Molecular imaging and biochemical response assessment after a single cycle of [<sup>225</sup>Ac]Ac-PSMA-617/[<sup>177</sup>Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [<sup>177</sup>Lu]Lu-PSMA-617 monotherapy
Florian Rosar, Fabian Hau, Mark Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish
Abstract
Lu]Lu-PSMA-617 monotherapy. Molecular imaging response and biochemical PSA response were mostly concordant, though a considerable number of cases (29.4%) were discordant. Molecular imaging response reflecting the change in total viable tumour burden appears to be superior to PSA change in estimating survival outcome after tandem therapy.
Topics & Concepts
MedicineConcordanceProgressive diseaseNuclear medicineInternal medicineProstate cancerProstate-specific antigenProstate carcinomaGlutamate carboxypeptidase IIProstateOncologyUrologyGastroenterologyDiseaseCancerProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis